Clinical study on posaconazole for the prophylaxis or salvage treatment of invasive fungal disease in patients with hematological diseases
10.3760/cma.j.issn.1009-9921.2015.12.007
- VernacularTitle:泊沙康唑预防或挽救性治疗血液病患者侵袭性真菌病的临床研究
- Author:
Changcheng ZHENG
;
Xiaoyu ZHU
;
Baolin TANG
;
Lei ZHANG
;
Huilan LIU
;
Zimin SUN
- Publication Type:Journal Article
- Keywords:
Mycoses;
Posaconazole;
Treatment outcome
- From:
Journal of Leukemia & Lymphoma
2015;24(12):732-735
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the efficacy and safety of posaconazole in the prophylaxis or salvage treatment of invasive fungal disease (IFD) in patients with hematological diseases.Methods 25 patients with hematological diseases receiving posaconazole treatment from Feb 2014 to Feb 2015 were analyzed retrospectively.The patients' average age was 32.6 years old (16-64 years old).18 patients received posaconazole for IFD prophylaxis, and 7 patients for IFD salvage treatment.Results 18 patients receiving posaconazole for IFD prophylaxis had no clinical manifestation of IFD (that is no case of breakthrough fungal infection) during treatment or in the 12 weeks after treatment, and the average prophylaxis period was 21 d (14-35 d).Among 7 patients receiving posaconazole for IFD salvage treatment, 6 patients were effective, including 4 cases cured and 2 cases effective.There were no obviously side effects of posaconazole in these patients.Conclusion Posaconazole has good clinical response for IFD in the hematologic diseases patients whether in prophylaxis or in salvage treatment.